The efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring driver mutations

The present retrospective study was conducted to evaluate the efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring driver mutations. Patients with NSCLC harboring driver mutations who received ICIs (nivolumab or pembrolizumab) were re...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Mol Clin Oncol
Main Authors: Sakamoto, Hiroaki, Tanaka, Hisashi, Shiratori, Toshihiro, Baba, Keisuke, Ishioka, Yoshiko, Itoga, Masamichi, Taima, Kageaki, Hasegawa, Yukihiro, Takanashi, Shingo, Tasaka, Sadatomo
Formato: Artigo
Idioma:Inglês
Publicado: D.A. Spandidos 2019
Assuntos:
Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6482391/
https://ncbi.nlm.nih.gov/pubmed/31031976
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2019.1838
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares